Two Clinical Trials Further Back Up Our FDA-Approved NEW DIETARY INGREDIENT!
For the past nearly 20 years, ANKASCIN 568-R has been proven by 120+ publications to be effective in managing blood lipids, blood sugar, blood pressure, and improving symptoms of Alzheimer’s disease through many animal tests conducted by Professor Tzu-Ming Pan from National Taiwan University, Taiwan. This year, two randomized double-blind placebo-controlled clinical trials on ANKASCIN 568-R have been finalized by Dr. Chin-Kun Wang at Chung Shun Medical University, Taiwan. One of the clinical trials indicated that, after 8 weeks of administration, levels of serum cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were statistically significantly reduced by 11.1% and 20.4%, respectively. The other clinical trial showed that, after 12 weeks of administration, fasting blood glucose (FBG) levels were statistically significantly reduced by 9.3%. Clinical results further support previous animal tests, confirming that the two new active compounds (Monascin and Ankaflavin) contained in this ingredient are multi-effective. Adding these results, ANKASCIN 568-R has been completed in full aspects of health benefits, safety, legality, and identity for quality assurance.
Related posts
Exciting News! SunWay’s Quality Receives National Recognition with SNQ Certification
The 2023 SNQ (Symbol of National Quality) Certification Ceremony was held on December 19th at the Grand Mayfull Hotel in Taipei, Taiwan. SunWay Biotech, a leading manufacturer of health and nutritional ingredients, boasts its flagship product ANKASCIN® 568-R, the only red yeast rice extract in the global market that does not contain “Monacolin K”. This product was developed by Professor Zi-Ming Pan and his professional R&D team over many years. Known as “NIANJIA Monascus Capsule”, this well-known health product is credited with regulating blood sugar, blood lipids, and anti-aging. Today, it was awarded the 2023 SNQ National Quality Mark Certificate, receiving certification in the category of nutritional health care/special functional health care ingredients. This certification represents another national-level recognition for SunWay Biotech and its “NIANJIA Monascus Capsule” product, following its achievement at the NutraIngredients Asia Awards – the ‘Oscars’ of health products – held in Singapore in September this year. The SNQ National Quality Mark, which also symbolizes “Safety and Quality”, communicates the goal of pursuing a healthy life and high-quality living. It aligns with SunWay Biotech’s corporate philosophy of “Quality First, Health Priority, Customer Foremost” and NIANJIA’s principle of “The Best for Protecting What We Love Most.”. Each year, the SNQ is based on an extremely strict review system and standard requirements, with “scientific evidence” at its […]
SunWay 2020 annual revenue was 314 million and will be listed on Taiwan Emerging Stock Market on January 18, 2021.
On January 12, SunWay Biotech Co., LTD. (1271) was invited by Fubon Securities Co., Ltd. to participate in the institutional investor conference. John Pan, President of SunWay Biotech, introduced two main ingredients-ANKASCIN 568-R and Vigiis 101-LAB probiotics and their application, and announced that SunWay Biotech will be listed on Taiwan Emerging Stock Market on January 18, 2021.
Congratulations! 沛安菌乳酸菌 of SunWay Biotech Co., LTD. is awarded The Symbol of National Quality in the Health Food Category by Institute for Biotechnology and Medicine Industry.
The Certficate of 2010 Symbol of National Quality